Artivion price target raised to $25 from $22 at Stifel

Stifel raised the firm’s price target on Artivion to $25 from $22 and keeps a Buy rating on the shares. Q1 sales came in “well-ahead” of the firm’s and consensus projections, while profitability also exceeded expectations, says the analyst, who contends that CEO Pat Mackin’s “strategy to build a robust and comprehensive aortic repair portfolio is successfully playing out.”